Unknown

Dataset Information

0

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients.


ABSTRACT:

Objectives

To evaluate the 1-year cost-effectiveness between three different initial treatment strategies in autoantibody-negative RA patients, according to 2010 criteria.

Methods

For this analysis we selected all RA patients within the intermediate probability stratum of the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial. The tREACH had a treat-to-target approach, aiming for low DAS <2.4, and treatment adjustments could occur every 3 months. Initial treatment strategies consisted of MTX 25 mg/week (initial MTX, iMTX), iHCQ 400 mg/day or an oral glucocorticoids tapering scheme without DMARDs (iGCs). Data on quality-adjusted life-years, measured with the European Quality of Life 5-Dimensions 3 Levels (EQ-5D-3L), healthcare and productivity costs were used.

Results

Average quality-adjusted life-years (s.d.), for iMTX, iHCQ and iGCs were respectively 0.71 (0.14), 0.73 (0.14) and 0.71 (0.15). The average total costs (s.d.) for iMTX, iHCQ and iGCs were, respectively, €10 832 (14.763), €11 208 (12.801) and €10 502 (11.973). Healthcare costs were mainly determined by biological costs, which were significantly lower in the iHCQ group compared with iGCs (P < 0.05). However, costs due to presenteeism were the highest in the iHCQ group (55%) followed by iMTX (27%) and iGCs (18%). The incremental cost-effectiveness ratios did not differ between treatment strategies. At a willingness-to-pay level of €50 000, the Dutch threshold for reimbursement of medical care, iHCQ had the highest probability (38.7%) of being cost-effective, followed by iGCs (31.1%) and iMTX (30.2%).

Conclusion

iHCQ had the lowest healthcare and highest productivity costs, resulting in a non-significant incremental cost-effectiveness ratio. However, iHCQ had the highest chance of being cost-effective at the Dutch willingness-to-pay threshold for healthcare reimbursement. Therefore, we believe that iHCQ is a good alternative to iMTX in autoantibody-negative RA patients, but validation is needed.

Clinical trial registration number

ISRCTN26791028.

SUBMITTER: Nathalie LM 

PROVIDER: S-EPMC8645278 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC10066987 | biostudies-literature
| S-EPMC8179789 | biostudies-literature
2021-11-30 | GSE189136 | GEO
| S-EPMC6939943 | biostudies-literature
| S-EPMC8995470 | biostudies-literature
| S-EPMC5732524 | biostudies-literature
| S-EPMC10551039 | biostudies-literature
| S-EPMC8735861 | biostudies-literature
| S-EPMC8876797 | biostudies-literature
| S-EPMC9208285 | biostudies-literature